- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01099618
Ketosis-Prone Diabetes Mellitus (KPDM): Metformin Versus Sitagliptin Treatment
Ketosis-Prone Diabetes in African Americans: Predictive Markers, Underlying Mechanisms, and Treatment Outcomes: The Effects of Metformin vs. Sitagliptin on Beta-Cell Preservation in Obese Subjects With Ketosis-Prone Type 2 Diabetes Mellitus
The study intends on enrolling 48 subjects with diabetes. Diabetic subjects that no longer need insulin will be randomly placed (like the flip of a coin) on a diabetes pill called metformin, a diabetes pill called sitagliptin or a placebo pill (a pill without active medication). Subjects on pills will be followed for 3½ years and undergo blood tests at specified intervals to assess their ability to make insulin. These studies will allow a better understanding of the factors that lead to high blood sugar in patients with ketosis-prone diabetes mellitus (KPDM) and direct the best diabetes treatment for this patient population.
Hypothesis: Metformin therapy or sitagliptin therapy compared to placebo, will improve β-cell function, insulin sensitivity, and allow for a longer period of time prior to encountering an insulin-deficient relapse after discontinuation of insulin therapy.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30303
- Grady Memorial Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- All newly diagnosed overweight/obese (BMI >/=28 kg/m2) African-American patients with new-onset DKA and/or severe hyperglycemia and without apparent precipitating cause will be considered for inclusion into the study. The diagnosis of DKA will be established by standard criteria (blood glucose > 250 mg/dL, pH < 7.3, HCO3 < 18 mmol/L, increased anion gap).
- The hyperglycemic group will include patients with an admission plasma glucose > 400 mg/dL but without the presence of metabolic acidosis or ketosis.
Exclusion Criteria:
- significant medical or surgical illness, including but not limited to myocardial ischemia, congestive heart failure, chronic renal insufficiency, liver failure, and infectious processes;
- recognized or suspected endocrine disorders associated with increased insulin resistance, such as hypercortisolism, acromegaly, or hyperthyroidism;
- bleeding disorders, thrombocytopenia, or abnormalities in coagulation studies;
- pregnancy,
- have an allergy to any component of metformin or sitagliptin.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Metformin
All newly diagnosed subjects with KPDM that are able to discontinue insulin after 12 weeks or less will be randomized in double-blind fashion to receive either metformin 1000mg, sitagliptin 100mg or placebo once daily.
Subjects that do not achieve remission will continue to receive insulin therapy and will discontinue the protocol.
A total of 48 obese subjects with DKA (N=24) and obese subjects with hyperglycemia without ketoacidosis (n=24) will be equally randomized to receive metformin (MET) 1000 mg (n=16), sitagliptin (SIT) 100mg (n=16) or placebo (n=16).
|
The study subject will receive metformin (MET) 1000 mg tablet once a day as long as the patient maintains near-normoglycemic remission (BG < 130mg/dL and A1c <7%) during the 3-year follow-up period.
Other Names:
|
Active Comparator: Sitagliptin
All newly diagnosed subjects with KPDM that are able to discontinue insulin after 12 weeks or less will be randomized in double-blind fashion to receive either metformin 1000 mg, sitagliptin 100mg or placebo once daily.
Subjects that do not achieve remission will continue to receive insulin therapy and will discontinue the protocol.
A total of 48 obese subjects with DKA (N=24) and obese subjects with hyperglycemia without ketoacidosis (n=24) will be equally randomized to receive metformin (MET) 1000 mg (n=16), sitagliptin (SIT) 100mg (n=16) or placebo (n=16).
|
The study subject will receive a sitagliptin 100mg once a day as long as the patient maintains near-normoglycemic remission (BG < 130mg/dL and A1c <7%) during the 3-year follow-up period.
Other Names:
|
Placebo Comparator: Placebo
All newly diagnosed subjects with KPDM that are able to discontinue insulin after 12 weeks or less will be randomized in double-blind fashion to receive either metformin 1000 mg, sitagliptin 100mg or placebo once daily.
Subjects that do not achieve remission will continue to receive insulin therapy and will discontinue the protocol.
A total of 48 obese subjects with DKA (N=24) and obese subjects with hyperglycemia without ketoacidosis (n=24) will be equally randomized to receive metformin (MET) 1000 mg(n=16), sitagliptin (SIT) 100mg (n=16) or placebo (n=16).
|
The study subject will receive a placebo tablet once a day as long as the patient maintains near-normoglycemic remission (BG < 130mg/dL and A1c <7%) during the 3-year follow-up period.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Length of Remission
Time Frame: 3 years
|
For those patients that are able to discontinue insulin therapy at or <12 weeks, how long were they able to well controlled with an A1c <7% on the agent that they were randomized to.
|
3 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Dawn D. Smiley, MD, Emory School of Medicine
Publications and helpful links
General Publications
- Vellanki P, Stefanovski D, Anzola II, Smiley DD, Peng L, Umpierrez GE. Long-term changes in carbohydrate tolerance, insulin secretion and action in African-American patients with obesity and history of hyperglycemic crises. BMJ Open Diabetes Res Care. 2020 May;8(1):e001062. doi: 10.1136/bmjdrc-2019-001062.
- Vellanki P, Smiley DD, Stefanovski D, Anzola I, Duan W, Hudson M, Peng L, Pasquel FJ, Umpierrez GE. Randomized Controlled Study of Metformin and Sitagliptin on Long-term Normoglycemia Remission in African American Patients With Hyperglycemic Crises. Diabetes Care. 2016 Nov;39(11):1948-1955. doi: 10.2337/dc16-0406. Epub 2016 Aug 29.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Immune System Diseases
- Autoimmune Diseases
- Endocrine System Diseases
- Acid-Base Imbalance
- Acidosis
- Hyperglycemia
- Diabetes Mellitus
- Diabetes Mellitus, Type 1
- Ketosis
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Protease Inhibitors
- Incretins
- Dipeptidyl-Peptidase IV Inhibitors
- Metformin
- Sitagliptin Phosphate
Other Study ID Numbers
- IRB00026272
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hyperglycemia
-
University of Colorado, DenverThe Leona M. and Harry B. Helmsley Charitable TrustRecruitingHypoglycemia | Menstruation Disturbances | Type 1 Diabetes | Hyperglycaemia Due to Type 1 Diabetes MellitusUnited States
-
National Research Council, SpainGenosa I+DRecruitingOverweight | PreDiabetesSpain
-
University of Colorado, DenverRecruitingObesity | PreDiabetes | Inactivity/Low Levels of ExerciseUnited States
-
Oregon Health and Science UniversityNot yet recruiting
-
University of Eastern FinlandRecruitingOverweight and Obesity | Postprandial Hyperglycemia | Type2diabetesFinland
-
City, University of LondonBarts & The London NHS TrustRecruitingVitamin D Status | Hyperglycemia, PostprandialUnited Kingdom
-
Universidad Europea de MadridRecruitingHyperglycemia | Hypoglycemia | Diabetes | Critical Care | Critically Ill PatientsSpain
-
Ain Shams UniversityRecruiting
-
University of New MexicoNot yet recruitingType 2 Diabetes Mellitus | PreDiabetesUnited States
-
University Hospital TuebingenRecruiting
Clinical Trials on metformin
-
University of Illinois at ChicagoEmily Hanners; Dulal Bhaumik; Avisek Datta; Peggy Choye; Hailey Soni; Annesti Elmasri; Julie Jun and other collaboratorsNot yet recruitingDiabetes Mellitus, Type 2United States
-
Oregon Health and Science UniversityNot yet recruiting
-
Johns Hopkins UniversityBaylor College of Medicine; National Heart, Lung, and Blood Institute (NHLBI); Temple UniversityNot yet recruitingAsthma | Overweight and Obesity | Asthma Chronic
-
Beijing Dongfang Biotech Co., Ltd.Not yet recruiting
-
Ping Li,MDNot yet recruitingPolycystic Ovary Syndrome | Non-Alcoholic Fatty Liver Disease
-
Bangabandhu Sheikh Mujib Medical University, Dhaka...Recruiting
-
Bio-innova Co., LtdNot yet recruiting
-
The University of Texas Health Science Center at...National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Not yet recruitingType 2 Diabetes (Adult Onset)United States
-
University Hospital "Sestre Milosrdnice"University of Zagreb School of MedicineNot yet recruitingOverweight | Type 2 Diabetes | Disordered Eating BehaviorsCroatia
-
International Bio serviceNot yet recruiting